AR080592A1 - Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso - Google Patents
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de pesoInfo
- Publication number
- AR080592A1 AR080592A1 ARP110100835A ARP110100835A AR080592A1 AR 080592 A1 AR080592 A1 AR 080592A1 AR P110100835 A ARP110100835 A AR P110100835A AR P110100835 A ARP110100835 A AR P110100835A AR 080592 A1 AR080592 A1 AR 080592A1
- Authority
- AR
- Argentina
- Prior art keywords
- gip
- peptide
- gln
- lys
- glp
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000004580 weight loss Effects 0.000 title abstract 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 3
- 102100040890 Glucagon receptor Human genes 0.000 abstract 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 2
- 102000014187 peptide receptors Human genes 0.000 abstract 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 108010011903 peptide receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un péptido que comprende la secuencia: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser- Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Arg-Ala -Xaa1-Val-Gln-Trp-Leu-Ile-Ala-Aib-Lys-Gly-Lys-Lys-Gln-Glu-Trp-Lys-His-Gln-Ile-Thr-Gln-Xaa2-Xaa (SEQ ID Ns:1) en donde Xaa1 en la posicion 22 es Nal o Phe; Xaa2 en la posicion 43 es Cys o ausente; Xaa3 en la posicion 44 es Cys o ausente; el aminoácido C-terminal está amidado opcionalmente; y siempre que cuando Xaa2 en la posicion 43 o Xaa3 en la posicion 44 sea Cys, entonces cualquiera o ambos son PEGilados opcionalmente. Este péptido exhibe actividad para el receptor de péptido insulinotropica dependiente de glucosa (GIP-R) y receptor de péptido 1 tipo glucagon (GLP-1-R) y son selectivos sobre el receptor de glucagon (Gluc-R). Específicamente se proveen análogos de GIP con sustituciones de aminoácido introducidas para modular la actividad para GIP-R y GLP-1-R y mantienen selectividad sobre Gluc-R. Formulacion farmacéutica que lo comprende. Su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la pérdida de peso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31785010P | 2010-03-26 | 2010-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080592A1 true AR080592A1 (es) | 2012-04-18 |
Family
ID=44041636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100835A AR080592A1 (es) | 2010-03-26 | 2011-03-16 | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8815811B2 (es) |
| EP (1) | EP2552471B1 (es) |
| JP (1) | JP5887335B2 (es) |
| KR (1) | KR101407775B1 (es) |
| CN (1) | CN102821779B (es) |
| AR (1) | AR080592A1 (es) |
| AU (1) | AU2011232597B2 (es) |
| BR (1) | BR112012024373A2 (es) |
| CA (1) | CA2794664A1 (es) |
| CL (1) | CL2012002635A1 (es) |
| CO (1) | CO6630128A2 (es) |
| CR (1) | CR20120457A (es) |
| DO (1) | DOP2012000244A (es) |
| EA (1) | EA022489B1 (es) |
| EC (1) | ECSP12012181A (es) |
| ES (1) | ES2568796T3 (es) |
| GT (1) | GT201200263A (es) |
| MA (1) | MA34077B1 (es) |
| MX (1) | MX2012011127A (es) |
| PE (1) | PE20130523A1 (es) |
| PH (1) | PH12012501899A1 (es) |
| SG (1) | SG184289A1 (es) |
| TN (1) | TN2012000432A1 (es) |
| TW (1) | TWI535450B (es) |
| WO (1) | WO2011119657A1 (es) |
| ZA (1) | ZA201206832B (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| EP2217701B9 (en) | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon antagonists |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| CN102123723B (zh) | 2008-06-17 | 2016-05-25 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
| SG192405A1 (en) | 2008-06-17 | 2013-08-30 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY |
| RU2012101274A (ru) | 2009-06-16 | 2013-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соединения глюкагона, активные в отношении рецептора gip |
| KR101809024B1 (ko) | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| WO2011143209A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| CN104093735B (zh) | 2011-09-23 | 2018-07-06 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| AU2013255751B2 (en) | 2012-05-03 | 2017-10-05 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| AR091422A1 (es) | 2012-06-14 | 2015-02-04 | Sanofi Sa | Analogos peptidicos de la exendina 4 |
| CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HRP20181300T1 (hr) | 2012-12-21 | 2018-10-05 | Sanofi | Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti |
| WO2014147124A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| MY174727A (en) * | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| UA118558C2 (uk) | 2013-05-28 | 2019-02-11 | Такеда Фармасьютікал Компані Лімітед | Пептидна сполука |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| AP2016009212A0 (en) | 2013-10-17 | 2016-05-31 | Zealand Pharma As | Acylated glucagon analogues |
| CA2929459C (en) * | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| EP3699187A1 (en) * | 2019-02-21 | 2020-08-26 | Universite D'angers | Peptide targeting gip and glp-2 receptors for treating bone disorders |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| EP4093757A1 (en) * | 2020-01-23 | 2022-11-30 | Eli Lilly and Company | Gip/glp1 co-agonist compounds |
| WO2021175974A1 (en) | 2020-03-06 | 2021-09-10 | Sanofi | Peptides as selective gip receptor agonists |
| AU2021233745B2 (en) * | 2020-03-11 | 2024-05-02 | Anygen Co., Ltd. | Composition for anti-diabetes and anti-obesity comprising novel compound |
| CA3216095A1 (en) * | 2021-05-28 | 2022-12-01 | Zhigan JIANG | Preparation and application of polypeptide |
| CN117440964A (zh) * | 2021-06-01 | 2024-01-23 | 南京知和医药科技有限公司 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
| EP4399224A1 (en) | 2021-09-06 | 2024-07-17 | Sanofi | New peptides as potent and selective gip receptor agonists |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| JP2024543441A (ja) * | 2021-11-19 | 2024-11-21 | メッドシャイン ディスカバリー インコーポレイテッド | ステープルペプチド及びその使用 |
| IL318334A (en) * | 2022-07-20 | 2025-03-01 | Viking Therapeutics Inc | Pharmaceutical formulations and methods for treating metabolic and liver disorders |
| WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
| KR20250141711A (ko) | 2022-12-30 | 2025-09-29 | 알지파마 에이에스 | 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법 |
| KR20240167410A (ko) | 2023-05-19 | 2024-11-26 | 주식회사 아울바이오 | 티르제파타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물 |
| WO2024252366A1 (en) | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| TW202517291A (zh) | 2023-06-30 | 2025-05-01 | 丹麥商西蘭製藥公司 | 組合療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| EP1883419A4 (en) * | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| WO2006121904A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| SG192405A1 (en) | 2008-06-17 | 2013-08-30 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| CN104231070B (zh) * | 2008-08-07 | 2017-09-01 | 益普生制药股份有限公司 | N‑端修饰的葡萄糖依赖性促胰岛素多肽（gip）类似物 |
| WO2010016940A2 (en) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| RU2012101274A (ru) | 2009-06-16 | 2013-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соединения глюкагона, активные в отношении рецептора gip |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
-
2011
- 2011-03-16 AR ARP110100835A patent/AR080592A1/es unknown
- 2011-03-18 TW TW100109463A patent/TWI535450B/zh not_active IP Right Cessation
- 2011-03-23 MA MA35233A patent/MA34077B1/fr unknown
- 2011-03-23 MX MX2012011127A patent/MX2012011127A/es active IP Right Grant
- 2011-03-23 PE PE2012001634A patent/PE20130523A1/es not_active Application Discontinuation
- 2011-03-23 EP EP11711424.9A patent/EP2552471B1/en active Active
- 2011-03-23 JP JP2013501419A patent/JP5887335B2/ja active Active
- 2011-03-23 KR KR1020127025038A patent/KR101407775B1/ko not_active Expired - Fee Related
- 2011-03-23 AU AU2011232597A patent/AU2011232597B2/en not_active Ceased
- 2011-03-23 WO PCT/US2011/029501 patent/WO2011119657A1/en not_active Ceased
- 2011-03-23 US US13/069,425 patent/US8815811B2/en active Active
- 2011-03-23 CA CA2794664A patent/CA2794664A1/en not_active Abandoned
- 2011-03-23 EA EA201270723A patent/EA022489B1/ru not_active IP Right Cessation
- 2011-03-23 CN CN201180016089.5A patent/CN102821779B/zh not_active Expired - Fee Related
- 2011-03-23 PH PH1/2012/501899A patent/PH12012501899A1/en unknown
- 2011-03-23 ES ES11711424.9T patent/ES2568796T3/es active Active
- 2011-03-23 SG SG2012071601A patent/SG184289A1/en unknown
- 2011-03-23 BR BR112012024373A patent/BR112012024373A2/pt not_active IP Right Cessation
-
2012
- 2012-08-30 TN TNP2012000432A patent/TN2012000432A1/en unknown
- 2012-09-07 CR CR20120457A patent/CR20120457A/es unknown
- 2012-09-07 DO DO2012000244A patent/DOP2012000244A/es unknown
- 2012-09-12 ZA ZA2012/06832A patent/ZA201206832B/en unknown
- 2012-09-24 CL CL2012002635A patent/CL2012002635A1/es unknown
- 2012-09-24 GT GT201200263A patent/GT201200263A/es unknown
- 2012-09-26 EC ECSP12012181 patent/ECSP12012181A/es unknown
- 2012-10-01 CO CO12171916A patent/CO6630128A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080592A1 (es) | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso | |
| AR079344A1 (es) | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad | |
| PE20240686A1 (es) | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) | |
| AR079345A1 (es) | Analogo peptidico de oxintomodulina | |
| CL2012003641A1 (es) | Compuesto analogo de glucagon que comprende sustituciones de los residuos aminoacidos en las posiciones 3 y/o 4 del glucagón nativo y que tiene actividad en el receptor de glucagon y/o el receptor de glp-1; composicion farmaceutica que comprende el compuesto; uso del compuesto para prevenir aumento de peso o promover perdida de peso en un sujeto que lo necesita. | |
| CL2011003173A1 (es) | Análogo del glucagón, agonista gip y glp-1; dímero que comprende el análogo de glucagón; conjugado con el análogo; composición que comprende dicho análogo; uso para preparar un medicamento para tratar diabetes, reducir el aumento de peso o inducir la pérdida de peso. | |
| CO6660484A2 (es) | Análogos de glucagón | |
| AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| PE20140186A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| EA201001801A1 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения | |
| PE20090108A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| PE20142113A1 (es) | Analogos de glucagon | |
| CL2009001424A1 (es) | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| BR112012028707A2 (pt) | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. | |
| AR077455A1 (es) | Preparaciones insulinicas de accion lenta | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| BR112015003916A2 (pt) | peptídeo selecionado a partir do grupo consistindo no peptídeo glp-1, no peptídeo gip e seus análogos resistentes a dipeptidil-peptidase iv (dpp-iv); e composição farmacêutica | |
| AR087727A1 (es) | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos | |
| GB2517871A (en) | Alternaria peptides | |
| TH151330A (th) | ส่วนเตรียมอินซูลินที่มีส่วนประกอบเมธิโอนีน | |
| UA109420C2 (uk) | Фармацевтична композиція, що включає агоніст glp-1, інсулін і метіонін |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |